The Nasonex 24HR Allergy Spray - Perrigo bets on familiar nasal relief in US aisles

By Elena Vance, ad hoc news New Launch Desk. Reviewed July 07, 2026, 4:42 PM ET. Details in the imprint.

Nasonex 24HR Allergy Spray sits at eye level in the allergy aisle, its blue-and-yellow box wedged between store-brand fluticasone and branded sprays, promising once-a-day relief in 120 metered sprays. The fine mist is almost scentless, a quick chill against the inside of your nose. For Perrigo Company PLC, this familiar over-the-counter workhorse is a quiet but important part of its US consumer health lineup.

Once-daily steroid spray with a long pedigree

Perrigo markets Nasonex 24HR Allergy Spray in the United States as an over-the-counter nasal corticosteroid containing mometasone furoate, a well-known active ingredient long used in prescription allergy products. Each spray delivers a measured dose designed for once-daily use in adults and children over a defined age, with dosing instructions emphasizing regular use rather than as-needed shots.

The product is positioned for relief of nasal allergy symptoms such as congestion, sneezing and runny nose related to seasonal or perennial allergic rhinitis, and its labeling highlights 24-hour efficacy when used as directed. On Perrigo’s US-focused consumer health pages, executives like CEO Patrick Lockwood-Taylor have described allergy care as a core pillar of the company’s self-care portfolio, with branded and private label nasal sprays both contributing to category scale.

US distribution through big-box and pharmacy chains

In practical terms for US shoppers, Nasonex 24HR Allergy Spray is sold through national chains including CVS, Walgreens and Walmart, as well as mass merchandisers and online marketplaces. Retail listings commonly show the 120-spray bottle as a standard pack size, often promoted as a 60-day or greater supply when dosed as one spray per nostril once daily, depending on age and physician guidance.

On a recent walk through a suburban New Jersey Walgreens, the Perrigo-produced Nasonex spray sat just to the right of a private-label fluticasone bottle, with a small shelf tag calling out a loyalty-card discount of a few dollars off the typical roughly mid-teens to low-twenties dollar price range per bottle. That positioning, shoulder-to-shoulder with store brands Perrigo also frequently manufactures, underlines the company’s dual strategy in allergy care.

Branded vs private label positioning

Perrigo is best known in the US for supplying store-brand healthcare products, but Nasonex 24HR sits on the branded side of its allergy portfolio, alongside other recognizable over-the-counter names. The company describes its US Consumer Self-Care Americas segment as including both national brands and retailer brands, providing scale in purchasing, manufacturing and distribution that can lower unit costs across the board.

On its brand overview page, Perrigo highlights allergy relief as a key category, with nasal sprays such as those based on mometasone and fluticasone forming one of the core product clusters. In investor presentations, Chief Financial Officer Eduardo Bezerra has pointed to steady demand in allergy products as one of the more defensive elements of Perrigo’s US portfolio, given the recurring nature of seasonal allergies.

Regulatory status and safety profile

Nasonex 24HR Allergy Spray is regulated in the United States as an over-the-counter drug, with labeling and formulation aligned to Food and Drug Administration requirements for mometasone nasal sprays. Consumers are advised to follow the package insert, which typically includes instructions on priming the pump, daily maximum doses and warning signs that should trigger a consultation with a healthcare provider.

Like other intranasal corticosteroids, mometasone can carry familiar side effects such as nasal irritation or nosebleeds, though the overall safety profile in approved dosing ranges is well established in clinical literature and long-term prescription use. Allergy specialists like Dr. Michael Blaiss have noted in peer-reviewed reviews that intranasal steroids remain a mainstay for moderate to severe allergic rhinitis because of their local effect in the nasal mucosa and limited systemic exposure when used correctly.

Competitive landscape on US shelves

On US store shelves, Nasonex 24HR competes directly with fluticasone-based sprays like Flonase and store-brand generics, as well as triamcinolone and budesonide products, each with slightly different branding angles around speed, scent or comfort. Market research from firms like IRI and Nielsen, frequently cited in industry commentary, shows nasal steroids capturing a substantial share of over-the-counter allergy spending, with consumers often trading between brands based on price and promotions rather than loyalty to one molecule.

Perrigo’s role as both manufacturer of retailer store-brand nasal sprays and brand owner of products like Nasonex 24HR gives it a broad footprint in that competition. In its most recent earnings commentary, management emphasized that private label share gains in US allergy could be complemented by branded products that command higher shelf visibility and, in some cases, better margins, though they face more direct consumer marketing demands.

Pricing dynamics and insurance backdrop

The roughly mid-teens to low-twenties dollar shelf price per bottle for Nasonex 24HR places it in line with other branded intranasal steroids but above many store-brand generics, which can retail several dollars cheaper depending on pack size and promotional cycles. In practice, that means a cost per day in the range of a few dozen cents, making regular use feasible for most insured and many uninsured consumers, though lower-cost generics may still be preferred for households managing multiple allergy sufferers.

Before its move into the US over-the-counter space, mometasone-based sprays like Nasonex were widely prescribed under insurance plans, with payers often steering patients toward preferred brands or generics, including store-brand equivalents supplied by Perrigo. The over-the-counter migration shifts decision-making to the consumer at the shelf, where packaging clarity, perceived efficacy, and recommendations from pharmacists like New York–based Dr. Stephanie Young can significantly sway choices.

Digital shelf, reviews and first-hand use

On major e-commerce platforms, Nasonex 24HR Allergy Spray listings show hundreds to thousands of user reviews, often clustered in the four-star range, with many buyers highlighting relief of congestion and improved sleep after several days of consistent use. Some reviewers complain about a mild chemical taste dripping into the throat or occasional dryness, familiar trade-offs for nasal steroid users.

Spraying Nasonex 24HR from a fresh bottle produces a fine, cool mist that coats the nasal passage within a second, followed by a faint medicinal tang at the back of the throat if the head is tilted too far. Pharmacists frequently advise tilting slightly forward and angling the nozzle away from the nasal septum to reduce irritation and maximize local distribution, an instruction in line with allergy society guidance.

Perrigo strategy and stock context

Perrigo has repeatedly told investors that its strategy centers on consumer self-care products under both brand and retailer labels, with the US allergy aisle a visible test case for that model. Nasonex 24HR Allergy Spray, while not a blockbuster by itself, exemplifies Perrigo’s focus on predictable, repeat-purchase categories where manufacturing scale and category expertise can drive stable revenue.

Shares of Perrigo Company PLC (NYSE: PRGO) give US investors exposure to that blend of branded and store-label self-care products, with allergy remedies such as Nasonex 24HR contributing to the company’s Consumer Self-Care Americas segment and its long-term cash generation potential.

This article was AI-assisted and editorially reviewed. Product information is provided without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Securities trading carries risks up to total loss.

en | IE00BGH1M568 | PERRIGO COMPANY PLC | boerse | 69717678 | bgmi